@article{3118294,
    title = "Patient compliance with alendronate, risedronate and raloxifene for the
treatment of osteoporosis in postmenopausal women",
    author = "Ringe, J. D. and Christodoulakos, G. E. and Mellstroem, D. and Petto, H. and and Nickelsen, T. and Marin, F. and Pavo, I.",
    journal = "Current Medical Research and Opinion",
    year = "2007",
    volume = "23",
    number = "11",
    pages = "2677-2687",
    publisher = "LIBRAPHARM/INFORMA HEALTHCARE",
    issn = "0300-7995, 1473-4877",
    doi = "10.1185/03007X226357",
    keywords = "bisphosphonates; compliance; discontinuation; osteoporosis;
postmenopausal women; raloxifene; tolerability",
    abstract = "Objectives: The aim was to investigate patient compliance with different
osteoporosis medications commonly prescribed in clinical practice, to
determine risk factors associated with discontinuation and to evaluate
quality of changes.
Research design and methods: We conducted a 1-year observational study
of patients of age >= 60 years in a clinical setting at 917 sites in 10
European countries (Germany, Greece, UK, Netherlands, Romania, Norway,
Finland, Estonia), Lebanon and South Africa. data, concomitant diseases,
the reasons for intervention, educational, socio-economical and disease
knowledge were captured at Self-reported compliance, discontinuation
data health status were collected.
Main outcome measures: Out of 5198 patients, 3490 (67.1%) patients
received 60 daily raloxifene (RAL), 452 (8.7%) 10 mg daily alendronate
(AQD), 769 (14.8%) 70 mg once weekly alendronate (AQW) and 487 (9.4%)
5 mg daily risedronate (RIS). Among patients completing the study (4231,
81%), the percentage of patients with high compliance was 80% (RAL),
79% (AOD), 65% (AQM and 76% (RIS). The discontinuation due to side
effects was highest on AQW (7.0%), followed by AQD (6.4%), RAL (3.8%)
and RIS (3.4%). The discontinuation-rate was higher for patients with a
history of surgical menopause, increased age, lack of knowledge about
medical prevention of osteoporosis and thin frame as a reason for
intervention. The EQ-5D weighted index showed the highest improvement
for RIS (0.13), followed by RAL (0.11), ADD (0.08) and AQW (0,07).
Conclusions: Data from this non-interventional observational study
indicate moderate overall compliance and discontinuation rate with the
prescribed osteoporosis medications."
}